ENGN
enGene Holdings Inc. · NASDAQ
- Sector Health Technology
- Industry Biotechnology
- Website engene.com
- Employees(FY) 31
- ISIN CA29286M1059
Performance
-7.11%
1W
-12.11%
1M
+79.45%
3M
+61.7%
6M
+54.17%
YTD
+34.82%
1Y
Profile
enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.
Technical Analysis of ENGN 2024-05-10
Overview:
In analyzing the technical indicators for ENGN over the last 5 days, we will delve into the trend, momentum, volatility, and volume indicators to provide a comprehensive outlook on the possible stock price movement in the coming days. By examining these key aspects, we aim to offer valuable insights and predictions to guide your invest...
Recent News & Updates
- 2024-05-02 16:05
- 2024-05-02 04:05
- 2024-04-23 06:56
Daily – Vickers Top Buyers & Sellers for 04/23/2024(Argus Research)
- 2024-04-09 08:00
- 2024-04-08 20:56
/C O R R E C T I O N -- enGene Inc./(Prnewswire)
- 2024-04-08 20:00
- 2024-03-11 16:05
- 2024-03-11 05:16
- 2024-03-05 07:00
- 2024-03-04 18:00
- 2024-02-14 06:50
- 2024-02-14 06:45
enGene Announces Leadership Succession Plan(PR Newswire)
- 2024-02-13 17:50
- 2024-02-13 17:45
enGene Announces Leadership Succession Plan(Prnewswire)
- 2024-01-30 07:00
- 2024-01-29 18:00
- 2024-01-29 07:00
- 2024-01-28 18:00
- 2023-12-22 17:00
- 2023-12-22 04:00
- 2023-12-19 07:00
- 2023-12-18 18:00
- 2023-11-28 18:00
- 2023-11-12 20:55
- 2023-11-01 19:00
- 2023-10-31 19:30
Page 1 of 1
previousnext